These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 17538942)

  • 1. Global benefit-risk assessment in designing clinical trials and some statistical considerations of the method.
    Pritchett YL; Tamura R
    Pharm Stat; 2008; 7(3):170-8. PubMed ID: 17538942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053
    [No Abstract]   [Full Text] [Related]  

  • 4. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
    Anderson GL; Kooperberg C; Geller N; Rossouw JE; Pettinger M; Prentice RL
    Clin Trials; 2007; 4(3):207-17. PubMed ID: 17715246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methodology of superiority vs. equivalence trials and non-inferiority trials.
    Christensen E
    J Hepatol; 2007 May; 46(5):947-54. PubMed ID: 17412447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interpretation of absolute measures of disease risk in comparative research.
    Replogle WH; Johnson WD
    Fam Med; 2007 Jun; 39(6):432-5. PubMed ID: 17549653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current controversies in data monitoring for clinical trials.
    Pocock SJ
    Clin Trials; 2006; 3(6):513-21. PubMed ID: 17170035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Communicating benefit and risk.
    Baglin T
    Br J Haematol; 2009 Jun; 146(1):31-3. PubMed ID: 19438473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential monitoring of randomization tests: stratified randomization.
    Zhang Y; Rosenberger WF; Smythe RT
    Biometrics; 2007 Sep; 63(3):865-72. PubMed ID: 17825016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e302-4. PubMed ID: 15173052
    [No Abstract]   [Full Text] [Related]  

  • 15. [Methodological and statistical aspects of equivalence and non inferiority trials].
    Elie C; De Rycke Y; Jais JP; Marion-Gallois R; Landais P
    Rev Epidemiol Sante Publique; 2008 Aug; 56(4):267-77. PubMed ID: 18703296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Methodological aspects of biostatistics and epidemiology in a clinical trial].
    Suárez E; Pérez CM
    P R Health Sci J; 1999 Mar; 18(1):23-30. PubMed ID: 10343983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations when designing a clinical trial of haematopoietic stem cell transplantation for autoimmune disease.
    Bredeson CN; Pavletic SZ
    Best Pract Res Clin Haematol; 2004 Jun; 17(2):327-43. PubMed ID: 15302344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The other side of clinical trial monitoring; assuring data quality and procedural adherence.
    Williams GW
    Clin Trials; 2006; 3(6):530-7. PubMed ID: 17170037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Test homogeneity of risk difference across subgroups in clinical trials.
    Zhang L; Yang H; Cho I
    J Biopharm Stat; 2009; 19(1):67-76. PubMed ID: 19127467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new 'mechanistic-practical" framework for designing and interpreting randomized trials.
    Karanicolas PJ; Montori VM; Devereaux PJ; Schünemann H; Guyatt GH
    J Clin Epidemiol; 2009 May; 62(5):479-84. PubMed ID: 18468856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.